ESPR – esperion therapeutics, inc. (US:NASDAQ)

News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com